ResMed (ResMed) Interest Expense

: $-59 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ResMed's interest expense for the three months ended in Dec. 2023 was $ -14 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-59 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ResMed's Operating Income for the three months ended in Dec. 2023 was $ 339 Mil. ResMed's Interest Expense for the three months ended in Dec. 2023 was $ -14 Mil. ResMed's Interest Coverage for the quarter that ended in Dec. 2023 was 24.58. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ResMed Interest Expense Historical Data

The historical data trend for ResMed's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

-36.16

-40.38

-23.99

-22.31

-47.38

ResMed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-10.34	-14.96	-14.94	-14.96	-13.81

ResMed Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59 Mil.

ResMed (NYSE:RMD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ResMed's Interest Expense for the three months ended in Dec. 2023 was $-14 Mil. Its Operating Income for the three months ended in Dec. 2023 was $339 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $1,357 Mil.

ResMed's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	339.322	/	-13.805
	=	24.58

The higher the ratio, the stronger the company's financial strength is.

ResMed (ResMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (NYSE:RMD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMEA:Germany RME:Germany RMEA:Germany RME:Germany R1MD34:Brazil RMD:Australia

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Executives

Brett Sandercock	officer: Chief Financial Officer	17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154
Michael J. Farrell	officer: Chief Executive Officer	C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123
Michael J Rider	officer: Global General Counsel	9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Robert Andrew Douglas	officer: President and COO	21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Kaushik Ghoshal	officer: President, SaaS Business	9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
David Pendarvis	officer: Chief Administration Officer	REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Karen Drexler	director	C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Justin Leong	officer: President, Asia and LATAM	C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Desney Tan	director	9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
John Hernandez	director	9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Lucile Blaise	officer: President, Sleep & RC Business	RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
James Hollingshead	officer: President, Sleep Business	C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Carol Burt	director	C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634
Resmed Inc	director	9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123